Ampligen Combined With SOC Versus SOC Alone Following First-Line Therapy in Subjects With LAPC
NCT05494697 · AIM ImmunoTech Inc.
Primary completion dateRecorded edit
− Previous value
2029-12
+ Updated value
2031-02
AIM
AIM ImmunoTech Inc.
Company identity checked against sources
See the trials and registry edits we have linked to this sponsor, the company or organization running a study. Choose “Follow company” to add it to your watchlist and find its recorded changes in your dashboard.
2Trials in this database
2Recorded changes · last 12 months
Partial coverageOnly the trials and history collected so far
Research sample: selected versions from May 2023 onward plus a preceding baseline where available. Only selected fields were retained; endpoint measures were truncated to 300 characters. This is not complete trial or sponsor history. Daily snapshots begin when collection starts.
Completion dates · Pro
Which trial dates moved later?
Pro summarizes how far estimated completion dates moved later and counts trials with edits to their main study measures, using the history available here. View Pro features
Included trials
Check company identity source| Trial | Sponsor | Phase | Status | Primary completion |
|---|---|---|---|---|
| Ampligen Combined With SOC Versus SOC Alone Following First-Line Therapy in Subjects With LAPCNCT05494697 | AIM | Phase 2 | Suspended | 2031-02Estimated |
| Study to Evaluate the Efficacy and Safety of Ampligen in Patients With Post-COVID ConditionsNCT05592418 | AIM | Phase 2 | Completed | 2023-11-17Actual |
Latest recorded trial changes
Ampligen Combined With SOC Versus SOC Alone Following First-Line Therapy in Subjects With LAPC
NCT05494697 · AIM ImmunoTech Inc.
Primary completion dateRecorded edit
− Previous value
2028-09
+ Updated value
2029-12